A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
